文献速递乳腺癌

基于乳腺X线摄影的乳腺癌风险模型的多机构验证

Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
PubMed 文献 · J Clin Oncol · 2021-11-12

研究在美国、以色列、瑞典、台湾和巴西的七家机构收集128,793张筛查乳腺X线摄影和病理确诊的乳腺癌结局,验证人工智能风险模型Mirai预测乳腺X线摄影后1至5年乳腺癌风险的Uno一致性指数。Mirai在七家机构的一致性指数为0.75至0.84,结论认为该模型在全球多样化测试集中保持准确性,是迄今最广泛的AI乳腺癌模型验证。

要点

  • 七家机构共纳入128,793张乳腺X线摄影,其中3,815张在5年内随访到癌症诊断。
  • Mirai预测1至5年乳腺癌风险的Uno一致性指数在七家机构为0.75至0.84。
  • 结论认为Mirai在全球多样化测试集中保持准确性,是迄今最广泛的AI乳腺癌模型验证。

核心结论

  • Mirai这一基于乳腺X线摄影的风险模型在全球五个国家七家医院的多样化测试集中保持准确性。
  • 这是迄今最广泛的AI乳腺癌模型验证,提示该技术可提供广泛且公平的诊疗改善。

研究设计与样本

  • 多机构验证研究,收集来自美国马萨诸塞州总医院、美国Novant、美国Emory、以色列Maccabi-Assuta、瑞典Karolinska、台湾长庚纪念医院和巴西Barretos的筛查乳腺X线摄影及病理确诊的乳腺癌结局。
  • 共收集七家机构128,793张乳腺X线摄影,来自62,185例患者,其中3,815张在5年内随访到癌症诊断。
  • 评估Mirai预测乳腺X线摄影后1至5年乳腺癌风险的Uno一致性指数。

主要发现

  • 马萨诸塞州总医院的一致性指数为0.75(95%CI,0.72至0.78)。
  • Novant的一致性指数为0.75(95%CI,0.70至0.80)。
  • Emory的一致性指数为0.77(95%CI,0.75至0.79)。
  • Maccabi-Assuta的一致性指数为0.77(95%CI,0.73至0.81)。
  • Karolinska的一致性指数为0.81(95%CI,0.79至0.82);长庚纪念医院为0.79(95%CI,0.76至0.83);Barretos为0.84(95%CI,0.81至0.88)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate risk assessment is essential for the success of population screening programs in breast cancer. Models with high sensitivity and specificity would enable programs to target more elaborate screening efforts to high-risk populations, while minimizing overtreatment for the rest. Artificial intelligence (AI)-based risk models have demonstrated a significant advance over risk models used today in clinical practice. However, the responsible deployment of novel AI requires careful validation across diverse populations. To this end, we validate our AI-based model, Mirai, across globally diverse screening populations. METHODS: We collected screening mammograms and pathology-confirmed breast cancer outcomes from Massachusetts General Hospital, USA; Novant, USA; Emory, USA; Maccabi-Assuta, Israel; Karolinska, Sweden; Chang Gung Memorial Hospital, Taiwan; and Barretos, Brazil. We evaluated Uno's concordance index for Mirai in predicting risk of breast cancer at one to five years from the mammogram. RESULTS: A total of 128,793 mammograms from 62,185 patients were collected across the seven sites, of which 3,815 were followed by a cancer diagnosis within 5 years. Mirai obtained concordance indices of 0.75 (95% CI, 0.72 to 0.78), 0.75 (95% CI, 0.70 to 0.80), 0.77 (95% CI, 0.75 to 0.79), 0.77 (95% CI, 0.73 to 0.81), 0.81 (95% CI, 0.79 to 0.82), 0.79 (95% CI, 0.76 to 0.83), and 0.84 (95% CI, 0.81 to 0.88) at Massachusetts General Hospital, Novant, Emory, Maccabi-Assuta, Karolinska, Chang Gung Memorial Hospital, and Barretos, respectively. CONCLUSION: Mirai, a mammography-based risk model, maintained its accuracy across globally diverse test sets from seven hospitals across five countries. This is the broadest validation to date of an AI-based breast cancer model and suggests that the technology can offer broad and equitable improvements in care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yala A, Mikhael PG, Strand F, et al. Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model. J Clin Oncol. 2021. PMID: 34767469. doi:10.1200/JCO.21.01337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。